Demonstrating Value To Payers: A Comprehensive Approach For Ensuring Patient Access To Cell And Gene Therapies

Cell & gene therapies (CGTs) are revolutionizing the medicine landscape by enabling efficacious treatments for severe or life-threatening diseases with previously unmet medical needs. However, the complexities of manufacturing and distributing these therapeutics is often costly. Sponsors must the challenge of demonstrating value to payers - an essential step in gaining patient access to these transformative therapies.

Payers, including insurance companies and government agencies, carefully evaluate the benefits and costs of CGTs before providing coverage. Sponsors must provide compelling clinical evidence that showcases the efficacy and safety of CGTs. A comprehensive approach that provides clinical evidence of efficacy and safety, demonstrates cost-effectiveness and long-term value, and focuses on the patient perspective is essential in building a strong value proposition.